Show simple item record

dc.contributor.authorCheung, A
dc.contributor.authorBax, HJ
dc.contributor.authorJosephs, DH
dc.contributor.authorIlieva, KM
dc.contributor.authorPellizzari, G
dc.contributor.authorOpzoomer, J
dc.contributor.authorBloomfield, J
dc.contributor.authorFittall, M
dc.contributor.authorGrigoriadis, A
dc.contributor.authorFigini, M
dc.contributor.authorCanevari, S
dc.contributor.authorSpicer, JF
dc.contributor.authorTutt, AN
dc.contributor.authorKaragiannis, SN
dc.date.accessioned2021-06-11T11:37:45Z
dc.date.available2021-06-11T11:37:45Z
dc.identifier.citationOncotarget, 2016, 7 (32), pp. 52553 - 52574
dc.identifier.issn1949-2553
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4617
dc.identifier.eissn1949-2553
dc.identifier.eissn1949-2553en_US
dc.identifier.doi10.18632/oncotarget.9651
dc.identifier.doi10.18632/oncotarget.9651en_US
dc.description.abstractPromising targeted treatments and immunotherapy strategies in oncology and advancements in our understanding of molecular pathways that underpin cancer development have reignited interest in the tumor-associated antigen Folate Receptor alpha (FRα). FRα is a glycosylphosphatidylinositol (GPI)-anchored membrane protein. Its overexpression in tumors such as ovarian, breast and lung cancers, low and restricted distribution in normal tissues, alongside emerging insights into tumor-promoting functions and association of expression with patient prognosis, together render FRα an attractive therapeutic target. In this review, we summarize the role of FRα in cancer development, we consider FRα as a potential diagnostic and prognostic tool, and we discuss different targeted treatment approaches with a specific focus on monoclonal antibodies. Renewed attention to FRα may point to novel individualized treatment approaches to improve the clinical management of patient groups that do not adequately benefit from current conventional therapies.
dc.formatPrint
dc.format.extent52553 - 52574
dc.languageeng
dc.language.isoeng
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectHumans
dc.subjectNeoplasms
dc.subjectFolate Receptor 1
dc.titleTargeting folate receptor alpha for cancer treatment.
dc.typeJournal Article
dcterms.dateAccepted2016-05-19
rioxxterms.versionVoR
rioxxterms.versionofrecord10.18632/oncotarget.9651
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
dc.relation.isPartOfOncotarget
pubs.issue32
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR
pubs.publication-statusPublished
pubs.volume7en_US
pubs.embargo.termsNot known
dc.contributor.icrauthorTutt, Andrewen


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/